In an official regulatory filing on September 14, 2026, Shivalik Rasayan Limited announced the outcome of its Board of Directors meeting held earlier today, approving a strategic capital raise aggregating to Rs. 30.75 Crores through a preferential allotment. The Board sanctioned the issuance of 2,82,000 equity shares of face value Rs. 5/- each at an issue price of Rs. 250/- per share (totaling Rs. 7.05 Crores) to public category investors including Ashwani Kumar Sharma, Harish Pande, Usha Pande, Deepa Pande, and Jaideep Mahesh Chandra Dwivedi. Furthermore, the company authorized the allotment of 9,47,990 fully convertible warrants at Rs. 250/- per warrant, aggregating to Rs. 23.70 Crores, to promoter entity Growel Remedies Limited (4,28,000 warrants) and public investors Bishnoi Exports Private Limited (1,20,000 warrants) and Ginnerup Capital ApS (3,99,990 warrants). Following the equity share allotment, the paid-up equity capital stands increased to Rs. 8.02 Crores, which will further expand to Rs. 8.49 Crores on a fully diluted basis upon warrant conversion.

The fresh capital infusion via preferential issue marks a significant corporate milestone for Shivalik Rasayan as it strengthens its balance sheet to fund ongoing expansion projects. The preferential allotment price of Rs. 250/- per share reflects strong investor confidence in the long-term execution capability of the management. Promoters demonstrating skin in the game by absorbing over 45% of the convertible warrants via Growel Remedies Limited reinforces alignment with public shareholders. The board meeting commenced at 3:15 PM and concluded at 4:00 PM, with all regulatory filings submitted in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Shivalik Rasayan Limited, established in 1979, is a premier Indian chemical and pharmaceutical manufacturing company headquartered in New Delhi. The company specializes in the manufacture of organophosphorus agrochemicals, active pharmaceutical ingredients (APIs), and specialized chemical intermediates, operating advanced manufacturing units at Dehradun (Uttarakhand) and Dahej-II (Gujarat), alongside a state-of-the-art R&D center at Bhiwadi (Rajasthan). Throughout 2025 and heading into 2026, the company has aggressively expanded its pharmaceutical CDMO and API business verticals to diversify beyond agrochemicals. Recent business updates highlight that Shivalik Rasayan has been scaling up production capacity at its Dahej facility, securing key regulatory approvals, and pursuing high-margin export orders for specialized oncology and non-oncology API molecules across global markets.

On the financial front, Shivalik Rasayan reported full-year annual revenues of Rs. 171.19 Crores for FY2025, representing a robust top-line growth of 13.15% YoY compared to Rs. 151.29 Crores recorded in FY2024. However, annual net profit for FY2025 stood at Rs. 8.17 Crores against Rs. 13.87 Crores in FY2024 due to margin compression from input raw material costs. Prominent market investors and institutional holders continue to track the firm as it transitions toward a higher-margin pharmaceutical mix.